Amgen gets early win in Regeneron lawsuit over Eylea biosimilar
Adds reponse from Regeneron to Sept 23 story in paragraph 4, corrects company locations in paragraphs 8 and 9
By Blake Brittain
Sept 23 (Reuters) -Regeneron REGN.O cannot immediately block U.S. sales of rival Amgen's AMGN.O proposed copy of its blockbuster eye-care drug Eylea, a federal judge in West Virginia said on Monday.
Regeneron has accused Amgen's biosimilar version of Eylea of infringing dozens of its patents. U.S. District Judge Thomas Kleeh on Monday rejected Regeneron's request for a preliminary injunction against Amgen as it pursues the patent lawsuit.
Eylea earned Regeneron $5.89 billion in U.S. sales in 2023. Regeneron stock was down 4.6% when markets closed on Monday afternoon.
Regeneron said in a statement on Tuesday that it was disappointed with the decision, and that it has no effect on the company's successes in similar cases against makers of other proposed Eylea biosimilars.The company said in a court filing on Monday that it had appealed.
An Amgen spokesperson said in a statement that the company was pleased with the decision and will announce its timeline for launching its biosimilar Pavblu "in due course."
The judge's decision explaining his denial was issued under seal.
Biosimilars are versions of biologic drugs that are comparable to generics of traditional pharmaceuticals. Unlike traditional drugs, complex biologic drugs are made from living cells and cannot be copied exactly.
The U.S. Food and Drug Administration approved Thousand Oaks, California-based Amgen's biosimilar of Eylea last month.
Tarrytown, N.Y.-based Regeneron's Eylea can be used to treat eye diseases like macular degeneration, macular edema and retinopathy. The FDA first approved the drug in 2011.
Regeneron has sued several other competitors over their proposed Eylea biosimilars, and brought its lawsuit against Amgen in California federal court in January. The case was moved to West Virginia in April.
The case is Regeneron Pharmaceuticals Inc v. Amgen Inc, U.S. District Court for the Northern District of West Virginia, No. 1:24-cv-00039.
For Regeneron: David Berl, Ellen Oberwetter, Thomas Fletcher, Andrew Trask, Teagan Gregory, Shaun Mahaffy and Kathryn Kayali of Williams & Connolly; Elizabeth Stotland Weiswasser, Anish Desai, Natalie Kennedy and Christopher Pepe of Weil Gotshal & Manges; Andrew Goldsmith, Evan Leo and Jacob Hartman of Kellogg, Hansen, Todd, Figel & Frederick
For Amgen: Jeffrey Lamken of MoloLamken; John Labbe and Kevin Flowers of Marshall, Gerstein & Borun; Anthony Figg, Joseph Hynds, Jennifer Nock and Brett Postal of Rothwell, Figg, Ernst & Manbeck
Read more:
Regeneron asks US court to block Amgen's Eylea biosimilar
Reporting by Blake Brittain in Washington
免責聲明: XM Group提供線上交易平台的登入和執行服務，允許個人查看和/或使用網站所提供的內容，但不進行任何更改或擴展其服務和訪問權限，並受以下條款與條例約束：（i）條款與條例；（ii）風險提示；（iii）完全免責聲明。網站內部所提供的所有資訊，僅限於一般資訊用途。請注意，我們所有的線上交易平台內容並不構成，也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。
所有缐上交易平台所發佈的資料，僅適用於教育/資訊類用途，不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議，或是交易價格紀錄，或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。
本網站的所有XM和第三方所提供的内容，包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接，皆爲‘按原狀’，並作爲一般市場評論所提供，而非投資建議。請理解和接受，所有被歸類為投資研究範圍的相關内容，並非爲了促進投資研究獨立性，而根據法律要求所編寫，而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊，相關詳情請點擊 這裡查看。
